tradingkey.logo

Amgen Inc

AMGN
384.320USD
+16.520+4.49%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
207.15BValor de mercado
26.81P/L TTM

Mais detalhes de Amgen Inc Empresa

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Informações de Amgen Inc

Código da empresaAMGN
Nome da EmpresaAmgen Inc
Data de listagemJun 17, 1983
CEOBradway (Robert A)
Número de funcionários28000
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 17
EndereçoOne Amgen Center Drive
CidadeTHOUSAND OAKS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91320-1799
Telefone18054471000
Sitehttps://www.amgen.com/
Código da empresaAMGN
Data de listagemJun 17, 1983
CEOBradway (Robert A)

Executivos da empresa Amgen Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
566.37K
+8478.00%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
69.05K
+2051.00%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
34.82K
-6879.00%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
17.19K
+809.00%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.93K
+612.00%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
7.57K
+809.00%
Dr. Wanda M. Austin, Ph.D.
Dr. Wanda M. Austin, Ph.D.
Independent Director
Independent Director
7.35K
+809.00%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
6.66K
-1116.00%
Ms. Nancy A. Grygiel
Ms. Nancy A. Grygiel
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
6.04K
--
Dr. Michael V. Drake, M.D.
Dr. Michael V. Drake, M.D.
Independent Director
Independent Director
4.89K
+219.00%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
566.37K
+8478.00%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
69.05K
+2051.00%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
34.82K
-6879.00%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
17.19K
+809.00%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.93K
+612.00%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
7.57K
+809.00%

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Other products
1.85B
19.39%
Prolia
1.14B
11.92%
Repatha
794.00M
8.31%
Otezla
585.00M
6.12%
Enbrel
580.00M
6.07%
Outro
4.61B
48.20%
Por RegiãoUSD
Nome
Receita
Proporção
US
6.33B
66.28%
ROW
2.26B
23.67%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Other products
1.85B
19.39%
Prolia
1.14B
11.92%
Repatha
794.00M
8.31%
Otezla
585.00M
6.12%
Enbrel
580.00M
6.07%
Outro
4.61B
48.20%

Distribuição de ações

Atualizado em: sáb, 15 de nov
Atualizado em: sáb, 15 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.14%
State Street Investment Management (US)
5.44%
BlackRock Institutional Trust Company, N.A.
5.30%
Capital International Investors
3.56%
Capital World Investors
3.49%
Outro
72.07%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.14%
State Street Investment Management (US)
5.44%
BlackRock Institutional Trust Company, N.A.
5.30%
Capital International Investors
3.56%
Capital World Investors
3.49%
Outro
72.07%
Tipos de investidores
Investidores
Proporção
Investment Advisor
53.91%
Investment Advisor/Hedge Fund
19.04%
Research Firm
4.88%
Pension Fund
2.21%
Bank and Trust
1.95%
Sovereign Wealth Fund
1.18%
Insurance Company
0.63%
Hedge Fund
0.42%
Individual Investor
0.17%
Outro
15.61%

Participação acionária institucional

Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
4407
451.47M
85.20%
+63.91K
2025Q3
4486
451.61M
85.29%
-1.24M
2025Q2
4487
452.85M
84.91%
+2.52M
2025Q1
4500
450.78M
83.12%
+3.88M
2024Q4
4470
440.57M
82.15%
+6.55M
2024Q3
4290
435.41M
82.39%
-1.01M
2024Q2
4260
436.06M
82.34%
+1.04M
2024Q1
4169
435.45M
81.98%
-3.93M
2023Q4
4130
433.32M
81.14%
+5.55M
2023Q3
3960
428.67M
80.98%
-560.79K
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
53.62M
9.96%
-236.61K
-0.44%
Sep 30, 2025
State Street Investment Management (US)
29.30M
5.44%
-52.93K
-0.18%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
28.53M
5.3%
-304.25K
-1.06%
Sep 30, 2025
Capital International Investors
19.19M
3.56%
+282.22K
+1.49%
Sep 30, 2025
Capital World Investors
18.80M
3.49%
+1.94M
+11.48%
Sep 30, 2025
Charles Schwab Investment Management, Inc.
13.55M
2.52%
+656.93K
+5.10%
Sep 30, 2025
Geode Capital Management, L.L.C.
13.27M
2.46%
+248.90K
+1.91%
Sep 30, 2025
Invesco Capital Management (QQQ Trust)
12.08M
2.24%
+795.62K
+7.05%
Dec 31, 2025
PRIMECAP Management Company
9.71M
1.8%
-924.10K
-8.69%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
8.89M
1.65%
+77.14K
+0.87%
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: seg, 1 de dez
Atualizado em: seg, 1 de dez
Nome
Proporção
VanEck Biotech ETF
12.81%
FT Vest DJIA Dogs 10 Target Income ETF
12.23%
ProShares Ultra Nasdaq Biotechnology
8.42%
Invesco Nasdaq Biotechnology ETF
8.35%
Simplify Health Care ETF
7.93%
iShares Biotechnology ETF
7.08%
Invesco Dow Jones Industrial Average Dividend ETF
6.24%
Amplify Weight Loss Drug & Treatment ETF
5.87%
Invesco Pharmaceuticals ETF
5.05%
Invesco Biotechnology & Genome ETF
5.01%
Ver Mais
VanEck Biotech ETF
Proporção12.81%
FT Vest DJIA Dogs 10 Target Income ETF
Proporção12.23%
ProShares Ultra Nasdaq Biotechnology
Proporção8.42%
Invesco Nasdaq Biotechnology ETF
Proporção8.35%
Simplify Health Care ETF
Proporção7.93%
iShares Biotechnology ETF
Proporção7.08%
Invesco Dow Jones Industrial Average Dividend ETF
Proporção6.24%
Amplify Weight Loss Drug & Treatment ETF
Proporção5.87%
Invesco Pharmaceuticals ETF
Proporção5.05%
Invesco Biotechnology & Genome ETF
Proporção5.01%

Dividendo

Um total de 17.60B USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Dec 09, 2025
AMGN.NB Interim Cash Dividend of gross USD 2.52 paid on Mar 06, 2026 going ex on Feb 13, 2026
Feb 13, 2026
Mar 06, 2026
Feb 13, 2026
Oct 31, 2025
AMGN.NB Final Cash Dividend of gross USD 2.38 paid on Dec 12, 2025 going ex on Nov 21, 2025
Nov 21, 2025
Dec 12, 2025
Nov 21, 2025
Aug 01, 2025
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Sep 12, 2025 going ex on Aug 22, 2025
Aug 22, 2025
Sep 12, 2025
Aug 22, 2025
Mar 04, 2025
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Jun 06, 2025 going ex on May 16, 2025
May 16, 2025
Jun 06, 2025
May 16, 2025
Dec 10, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 07, 2025
Feb 14, 2025
Oct 25, 2024
AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024
Nov 18, 2024
Dec 09, 2024
Nov 18, 2024
Aug 02, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 06, 2024
Aug 16, 2024
Mar 06, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024
May 17, 2024
Jun 07, 2024
May 16, 2024
Dec 12, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024
Feb 16, 2024
Mar 07, 2024
Feb 15, 2024
Oct 24, 2023
AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023
Nov 17, 2023
Dec 08, 2023
Nov 16, 2023
Ver Mais

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI